Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Intel Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Intel Corp trades at $109 (market cap $554.82B). The key difference: Intel Corp is far larger — about 123.6× ACADIA Pharmaceuticals Inc.'s market cap, and Intel Corp pays a 2.24% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | INTC | |
|---|---|---|
Market Cap | $4.49B | $554.82B |
Sector | Health | Technology |
52-Week High | $28.06 | $140.94 |
52-Week Low | $20.06 | $19.31 |
Enterprise Value | $3.69B | $567.06B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Intel (INTC) trades at $110.39, down 8.28% amid a sector-wide chip selloff triggered by Samsung's earnings reaction. Despite beating EPS estimates for three consecutive quarters, the stock shows weak profitability with a negative net income margin and ROE. Technical indicators are neutral, with support at $114 and resistance at $124. Cash flow improved in 2025, but revenue remains flat year-over-year, highlighting growth challenges.
The outlook is mixed: analyst consensus is a 'Hold' with a $97.74 price target below current levels, reflecting skepticism about near-term execution. Risks include intense competition and cyclical semiconductor demand, but potential upside exists if foundry partnerships and AI-driven CPU demand materialize as projected by bullish analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
